• Top Picks
    • The Role of Combination Therapies in Early, Intensive Treatment of Type 2 Diabetes
    • The Emerging Biosimilar Therapeutic Landscape: Scientific Foundations and Clinical Implications
    • Avoiding “Loss of Chance”…Improving the Screening, Treatment, and Referral of Patients with Diabetic Retinopathy
    • Prevention and Management of Diabetic Retinopathy and Related Eye Disorders: Clarifying the Endocrinologist’s Role

Select a Topic

  • FILTER BY:
J876
CME

Secondary Prevention of Atherothrombotic Events: Current Insights on Advancing Science

This activity is supported by an educational grant from Merck & Co.

Expiration Date: 12/22/2016
Credit Type(s): CME | Credit: 1.25

Prevention of cardiovascular disease (CVD) is critical in light of its associated mortality, morbidity, and economic burden. Preexisting conditions – including diabetes…

go to activity»
A Closer Look at CV Outcomes for Type 2 Diabetes Therapies: Implications for Patient Care
CMECE

A Closer Look at CV Outcomes for Type 2 Diabetes Therapies: Implications for Patient Care

This activity is supported by an educational grant from Merck & Co., Inc.

December 21, 2015

Patients with type 2 diabetes mellitus are at risk for cardiovascular disease and reducing this risk is a desirable outcome of therapy. Conflicting research on the CV…

go to activity»
J901 COVER
CMECNECPE

The Emerging Biosimilar Therapeutic Landscape: Scientific Foundations and Clinical Implications

This activity is supported by an educational grant from Boehringer-Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC.

Expiration Date: 12/10/2016
Credit Type(s): CME / CNE / CPE | Credit: 1.25

Recent processes have been established to facilitate the production, validation, and utilization of biosimilars. Biosimilars are therapeutic products similar in quality…

go to activity»
Advances in LDL Lowering: A Focus on PCSK9 Inhibitors’ Journey from Genetics to Clinical Practice
CMECE

Advances in LDL Lowering: A Focus on PCSK9 Inhibitors’ Journey from Genetics to Clinical Practice

This activity is supported by an educational grant from Amgen, Inc.

December 21, 2015

This Clinical Advances webcast discusses the relationship between atherosclerosis progression and LDL-C levels and provides expert interpretation of clinical guidelines…

go to activity»
The Role of Combination Therapies in Early, Intensive Treatment of Type 2 Diabetes
CMECE

The Role of Combination Therapies in Early, Intensive Treatment of Type 2 Diabetes

This activity is supported by an educational grant from AstraZeneca.

December 21, 2015

Despite the availability of numerous treatment options for type 2 diabetes mellitus, the number of patients achieving glycemic goals is unacceptably low. Some existing…

go to activity»
J871 Cover Image
CME

Navigating a New Era of Personalized Type 2 Diabetes Care: Taking the Road Less Traveled

This activity is supported by an independent educational grant from Boehringer-Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC.

Expiration Date: 11/19/2016
Credit Type(s): CME | Credit: 2

In the United States, over 29 million people have diabetes, of which approximately 95% of cases are type 2 diabetes mellitus (T2DM). While developments in the…

go to activity»
J876
CME

Secondary Prevention of Atherothrombotic Events: Current Insights on Advancing Science

This activity is supported by an educational grant from Merck & Co.

Expiration Date: 12/22/2016
Credit Type(s): CME | Credit: 1.25

Prevention of cardiovascular disease (CVD) is critical in light of its associated mortality, morbidity, and economic burden. Preexisting conditions – including diabetes…

go to activity»
Advances in LDL Lowering: A Focus on PCSK9 Inhibitors’ Journey from Genetics to Clinical Practice
CMECE

Advances in LDL Lowering: A Focus on PCSK9 Inhibitors’ Journey from Genetics to Clinical Practice

This activity is supported by an educational grant from Amgen, Inc.

December 21, 2015

This Clinical Advances webcast discusses the relationship between atherosclerosis progression and LDL-C levels and provides expert interpretation of clinical guidelines…

go to activity»
A Closer Look at CV Outcomes for Type 2 Diabetes Therapies: Implications for Patient Care
CMECE

A Closer Look at CV Outcomes for Type 2 Diabetes Therapies: Implications for Patient Care

This activity is supported by an educational grant from Merck & Co., Inc.

December 21, 2015

Patients with type 2 diabetes mellitus are at risk for cardiovascular disease and reducing this risk is a desirable outcome of therapy. Conflicting research on the CV…

go to activity»
The Role of Combination Therapies in Early, Intensive Treatment of Type 2 Diabetes
CMECE

The Role of Combination Therapies in Early, Intensive Treatment of Type 2 Diabetes

This activity is supported by an educational grant from AstraZeneca.

December 21, 2015

Despite the availability of numerous treatment options for type 2 diabetes mellitus, the number of patients achieving glycemic goals is unacceptably low. Some existing…

go to activity»
J901 COVER
CMECNECPE

The Emerging Biosimilar Therapeutic Landscape: Scientific Foundations and Clinical Implications

This activity is supported by an educational grant from Boehringer-Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC.

Expiration Date: 12/10/2016
Credit Type(s): CME / CNE / CPE | Credit: 1.25

Recent processes have been established to facilitate the production, validation, and utilization of biosimilars. Biosimilars are therapeutic products similar in quality…

go to activity»
J871 Cover Image
CME

Navigating a New Era of Personalized Type 2 Diabetes Care: Taking the Road Less Traveled

This activity is supported by an independent educational grant from Boehringer-Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC.

Expiration Date: 11/19/2016
Credit Type(s): CME | Credit: 2

In the United States, over 29 million people have diabetes, of which approximately 95% of cases are type 2 diabetes mellitus (T2DM). While developments in the…

go to activity»
Expert insight on hyperlipidemia

Watch as Christie Ballantyne, MD; Michael H. Davidson, MD; and Jennifer G. Robinson, MD, MPH provide insight on some of the hottest topics presented during the AHA…

go to activity»
Diabetic Retinopathy: The Importance of Early Screening, Referral, and Management
CME

Diabetic Retinopathy: The Importance of Early Screening, Referral, and Management

This activity is supported by an educational grant from Regeneron Pharmaceuticals, Inc.

Expiration Date: 11/15/2016
Credit Type(s): CME | Credit: 1.5

Diabetic eye disease is one of the most common causes of vision loss in the United States. As the rates of diabetes increase, the number of affected patients will rise…

go to activity»
Obesity Consults- Obesity Forums 2015 Highlights
CME

Obesity Consults® ObesityForum® 2015 Highlights

This activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc. and Novo Nordisk, Inc.

Expiration Date: 10/1/2016
Credit Type(s): CME | Credit: 1.25

Obesity has increased dramatically in the past 20 years and is considered a health care epidemic in the United States. According to the US Centers for Disease Control…

go to activity»
Managing Obesity in 2015: Setting the Framework and Assessing All of the Options
CME

Managing Obesity in 2015: Setting the Framework and Assessing All of the Options

This activity is supported by an educational grant from Novo Nordisk.

Expiration Date: 9/3/2016
Credit Type(s): CME | Credit: 1.75

This CME activity is based on the slides and lectures presented by the faculty at the symposium, Managing Obesity in 2015: Setting the Framework and Assessing All of the…

go to activity»
Prevention and Management of Diabetic Retinopathy
CME

Prevention and Management of Diabetic Retinopathy and Related Eye Disorders: Clarifying the Endocrinologist’s Role

This activity is provided by the American Association of Clinical Endocrinologists.

September 2, 2015

Diabetic retinopathy (DR) is a common microvascular complication of diabetes and the leading cause of blindness among working-age adults. Recent treatment advances that…

go to activity»
Avoiding “Loss of Chance”…
CME

Avoiding “Loss of Chance”… Improving the Screening, Treatment, and Referral of Patients with Diabetic Retinopathy

This activity is supported by an educational grant from Genentech, Inc.

Expiration Date: 9/1/2016
Credit Type(s): CME | Credit: 1.25

Despite a number of effective treatment options, diabetic eye disease is a leading cause of vision loss in the United States, in part because many patients are not…

go to activity»
Learn about a multisystem approach to treating your adult patients with type 2 diabetes
VIDEO

Victoza® liraglutide (rDNA origin) injection Mechanism of Action

This activity is sponsored by Novo Nordisk

August 13, 2015

In this video, learn how Victoza®, a GLP-1 receptor agonist, works in the body to compensate for the impaired incretin effect in adult patients with type 2 diabetes…

go to activity»
Diabetic Eye Cover Image
CME

Diabetic Eye 2015: New Concepts in Screening, Managing, and Referral

This activity is supported by an educational grant from Allergan, Inc.

Expiration Date: 8/10/2016
Credit Type(s): CME | Credit: 1.25

Despite a number of effective treatment options, diabetic eye disease is a leading cause of vision loss in the United States, in part because many patients are not…

go to activity»
Managing Today's EP Challenges with NOAC Use
CME

Managing Today's EP Challenges with NOAC Use

This activity is supported by independent educational grants from Boehringer Ingelheim Pharmaceuticals, Inc. and Daiichi Sankyo, Inc.

Expiration Date: 8/8/2016
Credit Type(s): CME | Credit: 1.25

This engaging activity featuring a superb faculty provides electrophysiologists and others with the best information available on managing stroke prevention around the…

go to activity»
Avoiding “Loss of Chance”…Improving the Screening, Treatment, and Referral of Patients with Diabetic Retinopathy
CME

Avoiding “Loss of Chance”…Improving the Screening, Treatment, and Referral of Patients with Diabetic Retinopathy

This activity is supported by an educational grant from Genentech, Inc.

Expiration Date: 7/23/2016
Credit Type(s): CME | Credit: 2

Despite a number of effective treatment options, diabetic eye disease is a leading cause of vision loss in the United States, in part because many patients are not…

go to activity»
Real-world Use of Anti-VEGF Therapy
CME

Real-world Use of Anti-VEGF Therapy

This activity is supported by an educational grant from Genentech, Inc.

Expiration Date: 4/25/2016
Credit Type(s): CME | Credit: 1.25

Anti-VEGF is well established as first-line therapy for the treatment of diabetic macular edema (DME) and age-related macular degeneration. What is still being…

go to activity»
morganatic-roan